The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study.
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; BC World Pharm; Boehringer Ingelheim; Bristol-Myers Squibb; ChongKeunDang Healthcare; Lilly; Menarini; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Samyang; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ST Cube
 
Ji-Youn Han
Stock and Other Ownership Interests - Yuhan
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - ABION; Bristol-Myers Squibb; J Ints Bio; Janssen; Lantern Pharma; Merck; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Charlotte Rose Lemech
No Relationships to Disclose
 
Michael Millward
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Guardant Health; IQvia; Lilly; Merck Serono; Novartis; Pfizer; Roche; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Relay Therapeutics (Inst); Turning Point Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst)
 
Aflah Roohullah
Employment - South Western Sydney Local Health District
 
Jun Young Choi
Leadership - Abion
Stock and Other Ownership Interests - Abion
Patents, Royalties, Other Intellectual Property - Abion
 
Kyung Eui Park
Employment - Abion
Stock and Other Ownership Interests - Abion
Patents, Royalties, Other Intellectual Property - Abion
 
Na Young Kim
Employment - Abion
Stock and Other Ownership Interests - Abion
Patents, Royalties, Other Intellectual Property - Abion
 
Sunyhe Im
Employment - Abion
 
Nirmal Rajasekaran
Employment - Abion
 
Sangsuk Lee
Employment - Abion
 
Hanlim Moon
Leadership - MediRama
 
Sunjin Hwang
Employment - MediRama
 
YOUNGKEE Shin
Leadership - Abion
Stock and Other Ownership Interests - Abion
Patents, Royalties, Other Intellectual Property - Abion
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck; Roche
Consulting or Advisory Role - AstraZeneca; BMS/Ono; IMBdx; Janssen; Lilly; Merck; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Lunit; Merck
Travel, Accommodations, Expenses - Novartis